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Objectives:  Nintedanib  is  an  oral  triple  angiokinase  inhibitor.  This  study  was conducted  to  evaluate  the
efﬁcacy  and  safety  of nintedanib  in patients  (pts)  with  relapsed/refractory  small  cell  lung  cancer  (SCLC).
Patients  and methods:  Pts with  an  ECOG  PS  from  0 to 2 who  exhibited  progression  after  one or  two  prior
chemotherapy  or chemo/radiotherapy  were  enrolled.  Pts  received  nintedanib  200  mg BID  daily  in a  4-
week cycle  until  progression  or intolerable  toxicity.  The  primary  end  point  was  the  objective  response
rate  (ORR).  A  two-stage  design  was  employed.  To  continue  to stage 2, ≥2  responders  out of  22 pts  were
required.
Results:  From  Dec  2011  to  June  2014,  24 pts  were  enrolled.  Twenty-two  pts  completed  treatment  and
were  evaluable  for  response.  The  median  follow-up  was  9.7 (0.5–19.8)  months.  The median  age  was  64
(46–77)  years.  Twenty-two  pts  were  male.  Six  pts  had  sensitive  relapse.  Eight  pts  received  one  prior
chemotherapy.  A median  of  one  (range  1–5) cycle  was  administered.  One  pt  had  a partial  response,
and  seven  pts  exhibited  stable  disease.  The  ORR was  5% (95%  conﬁdence  interval  [CI], 0.1–22.8).  Median
progression-free  survival  was  1.0  (95%  CI, 0.9–1.1)  month,  and  overall  survival  was  9.8  (95% CI,  8.4–11.2)
months.  The  response  criteria  to proceed  to full  accrual  were  not  met.  The  most  frequent  drug-related
adverse  events  (AE)  included  hepatic  enzyme  elevation  (86%),  anemia  (73%),  anorexia  (59%), and  nausea
(50%).  Most  AEs  were  mild  and  manageable.  Grade  3 hepatic  enzyme  elevation  occurred  in  5  pts  (23%).
Conclusions:  Nintedanib  exhibited  only  limited  activity  with  a  manageable  AE  proﬁle  in  relapsed  or
refractory  SCLC  (NCT01441297).
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
Despite a high initial response rate to chemotherapy, most
atients with small cell lung cancer (SCLC) experience relapse
ithin a year of completing ﬁrst-line therapy and die from systemic
etastases [1]. Although topotecan is regarded as the standard
econd-line therapy, the response rate is modest, and survival rates
emain unsatisfactory [2,3]. Therefore, more effective novel agents
re required for relapsed SCLC.
Human SCLC cells express functional vascular endothelial
rowth factor receptor (VEGFR)-2, VEGFR-3 and platelet-derived
rowth factor receptor (PDGFR)- [4,5]. In addition, stem cell fac-
or (SCF) and its receptor KIT are co-expressed in up to 70% of SCLC
ell lines and clinical SCLC samples [6]. Therefore, we  previously
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169-5002/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
conducted a phase II study on sunitinib, a multi-target tyrosine
kinase inhibitor that is effective against VEGFR-1, VEGFR-2, VEGFR-
3, PDGFR and KIT, in patients with relapsed or refractory SCLC.
The response rate was  9% (2/23), and the disease control rate was
39% (9/23). However, most patients were unable to tolerate the
sunitinib treatment due to signiﬁcant toxicity, which resulted in
frequent sunitinib dose interruptions. The actual dose intensity (the
actual dose delivered as a proportion of the planned dose with or
without delay) of sunitinib was 69.7%, which may  have led to the
relatively low efﬁcacy [7]. In contrast, a recent randomized phase
II trial demonstrated that maintenance sunitinib after chemother-
apy improved progression-free survival (PFS) in untreated patients
with extensive-disease (ED)-SCLC. In addition, the overall survival
(OS) was promising despite the cross-over design. These ﬁnd-
ings suggest that multi-targeted VEGFR inhibitors may be effective
against SCLC [8].Nintedanib is a potent, oral angiokinase inhibitor that targets
the pro-angiogenic pathways mediated by VEGFR1-3, ﬁbroblast
growth factor receptor (FGFR) 1-3, and PDGFR  and  [9]. FGFR1
is ampliﬁed in 6% of SCLC, and sensitivity to FGFR inhibitors has
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Table  1
Baseline characteristics of patients.
Characteristics Patient No.
Age, years Median (range) 64 (46–77)
Gender Male 22
Female 2
ECOG PS 0 1
1  11
2  12
Smoking Median (range), pack-year 39 (11–94)
Ever 21
Never 3
Prior therapy No One 8
Two  16
Relapse pattern Sensitive 6
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Table 2
Adverse events.
Grade 1 Grade 2 Grade 3 Grade 4
N (%) N (%) N (%) N (%)
Hematologic
Anemia 12 (50) 6 (25) 0 (0) 0 (0)
Thrombocytopenia 6 (25) 0 (0) 0 (0) 0 (0)
Leukopenia 5 (21) 0 (0) 0 (0) 0 (0)
Neutropenia 0 (0) 2 (8) 1 (4) 0 (0)
Non-hematologic
ALT elevation 5 (21) 9 (38) 5 (21) 0 (0)
AST elevation 5 (21) 9 (38) 2 (8) 0 (0)
Anorexia 6 (25) 7 (29) 0 (0) 0 (0)
Fatigue 7 (29) 5 (21) 1 (4) 0 (0)
Nausea 7 (29) 5 (21) 0 (0) 0 (0)
Diarrhea 8 (33) 1 (4) 0 (0) 0 (0)
Pain 4 (17) 5 (21) 0 (0) 0 (0)
Vomiting 5 (21) 1 (4) 0 (0) 0 (0)
Constipation 5 (21) 1 (4) 0 (0) 0 (0)
Abdominal pain 4 (17) 1 (4) 0 (0) 0 (0)
Epigastric soreness 3 (12) 3 (12) 0 (0) 0 (0)
Myalgia 2 (8) 2 (8) 0 (0) 0 (0)
Dyspepsia 3 (12) 0 (0) 0 (0) 0 (0)
Rash 2 (8) 1 (4) 0 (0) 0 (0)
Headache 2 (8) 1 (4) 0 (0) 0 (0)
Neuropathy-sensory 0 1 (4) 0 (0) 0 (0)
Mucositis 1 (4) 0 (0) 0 (0) 0 (0)
Dry mouth 1 (4) 0 (0) 0 (0) 0 (0)
each treatment cycle. The response assessment was performed atResistant or refractory 18
een described in some, but not all, SCLC [10]. Recently, a random-
zed phase III study demonstrated a survival beneﬁt of nintedanib
n combination with docetaxel versus docetaxel alone in previ-
usly treated lung adenocarcinoma. In addition, nintedanib alone
xhibited a manageable toxicity proﬁle in phase I/II trials [11,12].
iven the potential activity through the inhibition of angiogenesis
nd a favorable toxicity proﬁle, we conducted a phase II study of
intedanib in patients with relapsed or refractory SCLC.
. Patients and methods
.1. Eligibility criteria
Patients with ED-SCLC who progressed during or after treat-
ent with at least one platinum-based chemotherapy were eligible
or inclusion in the study. Patients, who have relapsed beyond 3
onths of completing ﬁrst-line treatment, were considered as the
ensitive relapse. Patients who have progressed within 3 months
ere considered as the refractory relapse. Patients, who did not
espond or relapsed during ﬁrst-line treatment, were considered
s resistant [13]. All patients displayed measurable disease by the
esponse Evaluation Criteria in Solid Tumors (RECIST), an East-
rn Cooperative Oncology Group (ECOG) performance status (PS)
f less than or equal to 2, adequate hepatic, renal and hema-
ologic function, and normal thyroid function. Additionally, all
atients were at least 18 years of age. Patients were excluded
f they presented a grade 3 hemorrhage based on the National
ancer Institute (NCI) Common Terminology Criteria for Adverse
vents (CTCAE) or gross hemoptysis (>5 mL  of blood per episode
nd >10 mL  of blood/d) less than 4 weeks prior to the onset of
reatment. Prior treatment with anti-angiogenic agents was  not
ermitted. Additional exclusion criteria included the following:
ncontrolled hypertension; a diagnosis of any second malignancy
ithin the preceding 3 years (except for adequately treated basal
ell or squamous cell skin cancer or in situ carcinoma of the
ervix uteri); a history of or current brain metastases, spinal cord
ompression, carcinomatous meningitis or evidence of brain or lep-
omeningeal disease; clinically signiﬁcant cardiovascular disease
severe/unstable angina, myocardial infarction, coronary artery
ypass graft, or symptomatic congestive heart failure); pulmonary
mbolism or cerebrovascular accident within the 12 months prior
o the study drug administration; a history of a decline in the left
entricular ejection fraction below the lower limit of normal or
ngoing cardiac dysrhythmias (NCI CTCAE grade ≥2), and atrial
brillation or prolongation of the QTc interval. All patients with
eproductive potential were required to use contraception during
reatment. All patients were required to provide written informed
onsent prior to entry into the study.Hand-foot syndrome 1 (4) 0 (0) 0 (0) 0 (0)
Hyponatremia 1 (4) 0 (0) 0 (0) 0 (0)
Hyperglycemia 1 (4) 0 (0) 0 (0) 0 (0)
2.2. Study design
This was  an open-label, single-arm, phase II study conducted at
a single center (National Cancer Center, Goyang, Korea). The pri-
mary end point was  the objective response rate (ORR), deﬁned as
the percentage of all patients who experienced a conﬁrmed com-
plete response or partial response (PR) based on RECIST1.1 [14].
The secondary end points included safety and tolerability, PFS and
OS. The protocol was  approved by an independent ethics commit-
tee/institutional review board and was conducted in accordance
with the Declaration of Helsinki, Good Clinical Practice.
2.3. Study treatment
The patients received nintedanib 200 mg orally twice daily
every 4 weeks. In the case of treatment-related adverse events,
nintedanib dose reductions were performed accordingly by 25%
for each additional toxicity grade (i.e., 25% for grade 2 and 50% for
grade 3 toxicity). Treatment was continued until tumor progres-
sion, withdrawal of consent or unacceptable toxicity, deﬁned as
grade 4 hematologic toxicity and grade ≥ 3 non-hematologic toxi-
city inducing a persistent delay in administration of the next cycle
beyond day 42 of each cycle.
2.4. Assessment
The baseline evaluations included medical history, physical
examination, tumor imaging with computed tomography or a
magnetic resonance imaging scan, laboratory tests (hematology,
urinalysis, coagulation, blood chemistry and pregnancy tests), three
12-lead electrocardiogram (ECGs) and echocardiography. Hematol-
ogy, blood chemistry and thyroid function (T3, thyroid-stimulating
hormone (TSH), and free T4) evaluations were performed beforethe end of dosing in cycles 1 and 2 followed by every two  cycles
according to the RECIST criteria 1.1. Initially, tumor responses
were evaluated by the investigator. Subsequent to the evaluation
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Fig. 1. Patient survival. (A) Progression-free survival. (B) Overall survival.
Table 3
Clinical trials of antiangiogenic agents in relapsed small cell lung cancer.
Authors Study drug Study design Relapse pattern Patients (n) ORR (%) mPFS (mo) mOS  (mo)
Jadal et al. Bevacizumab Paclitaxel Single arm, phase II Sensitive 34 18 3.4 6.9
Mountzios et al. Bevacizumab Paclitaxel Single arm, phase II Resistant 30 20 2.7 6.3
Allen et al. Aﬂibercept Topotecan Two  arms, randomized phase II Sensitive or resistant 189 2 1.8 6.0
Ramalingam et al. Cediranib – Single arm, phase II Sensitive or resistant 25 0 2.0 6.0
Han  et al. Sunitinib – Single arm, phase II Sensitive or resistant 25 9 1.4 5.6
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RR, overall response rate; mPFS, median progression-free survival; mOS, median 
y the investigator; all measurable and non-measurable lesions
ere independently assessed by two referee radiologists who  were
linded to the treatment assignment (Kim HY, Lim KY). Toxicity was
raded according to the National Cancer Institute Common Toxicity
riteria version 4.0.
.5. Statistical analyses
The primary objective of this phase II trial was  to assess the
verall ORR in patients with relapsed SCLC treated with single agent
intedanib. It was hypothesized that nintedanib would result in
n objective response of >20% (single agent topotecan activity in
elapse SCLC) in the intent-to-treat population. This trial employed
 Simon optimal design. For a total of 41 evaluable subjects, 22
ere accrued during stage 1, and 19 were accrued during stage 2.
f fewer than 2 patients respond to therapy during stage 1, accrual
as stopped, and it would be concluded that this therapy regimen
ould not merit further study. The alpha level of the design is 0.05;
nd the power is 0.9. Efﬁcacy outcomes are based on intent-to-treat
nalyses. PFS is deﬁned as the interval between the start date of
reatment and the date of occurrence of PD or death. OS is measured
rom the date of study entry until the date of death. Dose-intensity
as calculated by using the method of Hryniuk and Bush [15].
. Results.1. Patient characteristics
From Dec 2011 to June 2014, 24 patients were enrolled, and 22
eceived at least one cycle of nintedanib. Two patients withdrewSensitive or resistant 22 5 1.0 9.8
l survival.
from the study within 1 week after the ﬁrst dose of nintedanib. The
baseline characteristics of the enrolled patients are listed in Table 1.
The median age was  64 years, and 22 of the patients were male.
Eight patients who  received one platinum-based chemotherapy
exhibited resistant relapse. Among 16 patients who  received two
prior chemotherapy regimens, 10 exhibited refractory relapses.
3.2. Toxicity
All patients who  received at least one dose of therapy were
assessable for toxicity. Toxicity was reported as the maximum tox-
icity experienced during the study treatment (Table 2). The most
common adverse event (AE) was  hepatic enzyme elevation (80%).
A grade 3 hepatic enzyme elevation occurred in 5 patients (21%).
Most AEs were mild and manageable. No treatment-related deaths
were noted.
3.3. Treatment adherence
Patients received a median of one (range 1–5) cycle. Overall,
a total of 38 treatment cycles were administered as per proto-
col, among which 9 (24%) were delayed. The main reason for
treatment delay and subsequent dose modiﬁcations were aspar-
tate transaminase (AST)/alanine transaminase (ALT) elevations
(n = 7) and neutropenia (n = 2). The median dose-intensity was
372 mg/day (93% of the planned dose). The reason for treatment
discontinuation was  disease progression during treatment in all
cases.
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.4. Response and survival
A total of 22 patients were evaluable for response. One patient
xhibited a PR, and seven exhibited stable disease (SD). Among 7
atients with SD, three showed some dregree of tumor shrinkage.
he ORR was 5% (95% conﬁdence interval (CI), 0.1–22.8) and the
isease control rate (PR + SD) was 36% (95% CI, 17–59). The cutoff
or the OS update was June 25, 2015, and the median follow-up time
as 9.7 months (range, 0.5–19.8 months). The median PFS and OS
ere 1.0 (95% CI, 0.9–1.1) month and 9.8 (95% CI, 8.4–11.2) months,
espectively (Fig. 1A, B).
. Discussion
Despite the substantial scientiﬁc rationale for antiangiogenic
gents in SCLC, few studies have demonstrated a clinical beneﬁt. So
ar, topotecan is the only agent approved for second-line therapy
or sensitive relapsed SCLC. In an early phase II study of topotecan
s a second-line therapy in both platinum-sensitive and refrac-
ory patients, ORRs of 37.8% and 6.4%, respectively, were reported.
he overall median time to progression was 2.8 months and the
S was 5.4 months [2,3]. Recently, a randomized phase II study
ompared topotecan with or without aﬂibercept, a recombinant
usion protein consisting of VEGF-binding portions from the extra-
ellular domains of human VEGFR1 and 2 that are fused to the Fc
ortion of human IgG1. Although aﬂibercept improved 3-month
FS in platinum-refractory SCLC (27% vs. 10%, P = 0.02), no signiﬁ-
ant difference in OS was noted. In the study, the median PFS and
edian OS were 1.3 months and 4.6 months, respectively, in sensi-
ive relapsed SCLC. These values were 1.4 months and 4.2 months,
espectively, in refractory relapsed SCLC with topotecan alone [16].
able 3 summarized the clinical trials of antiangiogenic agents
n relapsed SCLC [7,16–19]. All studies demonstrated only mod-
st activity; however, these results are comparable with topotecan
lone in patients with relapsed SCLC.
The primary endpoint of this study was RR. However, the
urrogate endpoints have not been widely established for SCLC.
dditionally, a decrease in response rate (RR) has been noted over
he past 25 years in SCLC studies, which has been well demon-
trated in topotecan efﬁcacy in relapsed SCLC. It is likely that the
se of more sensitive imaging technology to evaluate the response
ay  contribute to the decreased RR in SCLC [20]. Moreover, antian-
iogenic agents can result in increased efﬁcacy in the absence of a
obust response based on RECIST. This phenomenon has been well
emonstrated in a phase III study of sorafenib in hepatocellular car-
inoma, in which sorafenib improved PFS and OS despite an RR of
nly 2.3% [21]. Although our study did not meet the efﬁcacy criteria
o proceed to full accrual after interim analysis, the median OS of
.8 months observed in our study may  suggest a potential survival
eneﬁt from nintedanib in SCLC.
In contrast to the limited activity of antiangiogenic agents in
elapsed SCLC, sunitinib as a maintenance therapy after induc-
ion chemotherapy improved PFS in ED-SCLC. The median OS for
he sunitinib maintenance arm was 2.1 months longer than the
lacebo arm, but the difference was not statistically signiﬁcant.
lthough the authors concluded that sunitinib maintenance was
afe and feasible, grade 3 or 4 toxicities were reported in 39%
17/44) of patients who received sunitinib. In addition, 21 (48%)
atients required sunitinib dose modiﬁcations [8]. Previously, we
lso reported that sunitinib was not tolerated mainly due to throm-
ocytopenia, asthenia and neutropenia. [7] In this study, the main
eason for treatment delay and subsequent dose modiﬁcations
ere AST/ALT elevations and neutropenia. However, most patients
olerated nintedanib treatment. No cases of treatment interruption
ue to unacceptable toxicity were reported. The median dose-
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intensity was  372 mg/day, which accounts for 93% of planned doses.
Given the manageable toxicity proﬁle and the potential OS beneﬁt,
nintedanib could be considered as a maintenance therapy in SCLC.
In this single-arm phase II study, nintedanib exhibited limited
activity but was  well tolerated in patients with relapsed SCLC.
Although the primary end point of ORR and thus the prerequi-
site to proceed with full accrual as per the trial design was not
achieved, it is worth noting that seven patients had stable disease,
and one patient exhibited a partial response following nintedanib
treatment. Furthermore, the median OS of 9.8 months observed in
these patients with a poor prognosis appears promising.
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